Tan CR, Asoori S, Huang CY, Brunaldi L, Popat R, Kastritis E, Martinez-Lopez J, Bansal R, Silva Corraes AM, Chhabra S, Parrondo R, Ailawadhi S, Fotiou D, Dimopoulos MA, Yong K, Mactier C, Lau C, Corona M, Marin AJS, Mian H, Durie BG, Usmani SZ, Martin TG, Lin Y. Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study. Blood Cancer J. 2025 Apr 03; 15(1):53.

Mittal K, Joshi M. Perioperative immunotherapy in urothelial carcinoma: AMBASSADOR charts the path forward. Med. 2024 Dec 13; 5(12):1449-1451.

Challapalli A, Stewart G, Shaw H, Davies PJ, Lopez-Baez JC, Ottley EC, Kelly S. Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (Real World evidence of advanced CSCC treatment with cemiplimab). Front Immunol. 2024; 15:1408667.

Kim AE, Lou KW, Giobbie-Hurder A, Chang K, Gidwani M, Hoebel K, Patel JB, Cleveland MC, Singh P, Bridge CP, Ahmed SR, Bearce BA, Liu W, Fuster-Garcia E, Lee EQ, Lin NU, Overmoyer B, Wen PY, Nayak L, Cohen JV, Dietrich J, Eichler A, Heist R, Krop I, Lawrence D, Ligibel J, Tolaney S, Mayer E, Winer E, Perrino CM, Summers EJ, Mahar M, Oh K, Shih HA, Cahill DP, Rosen BR, Yen YF, Kalpathy-Cramer J, Martinez-Lage M, Sullivan RJ, Brastianos PK, Emblem KE, Gerstner ER. Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance. Neuro Oncol. 2024 05 03; 26(5):965-974.

Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk NWCJ, Leleu X, G?llego P?rez-Larraya J, Manier S, Nooka AK, Mateos MV, Einsele H, Minnema M, Cavo M, Derman BA, Puig N, Gay F, Ho PJ, Chng WJ, Kastritis E, Gahrton G, Weisel K, Nagarajan C, Schjesvold F, Mikhael J, Costa L, Raje NS, Zamagni E, H?jek R, Weinhold N, Yong K, Ye JC, Sidhana S, Merlini G, Martin T, Lin Y, Chari A, Popat R, Kaufman JL. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024 05; 25(5):e205-e216.

Margalit O, Lieberman S, Redinsky I, Halparin S, Honig N, Raskin S, Ben-Ayun M, Shacham-Shmueli E, Halpern N, Urban D, Ackerstein A, Shulman K, Ben-Ami E, Semenisty V, Purim O, Yarom N, Golan T, Boursi B, Appel S, Symon Z, Berger R, Mauro D, Krieg AM, Lawrence YR. Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases. Clin Colorectal Cancer. 2023 12; 22(4):442-449.e1.

Dora D, Ligeti B, Kovacs T, Revisnyei P, Galffy G, Dulka E, Krizs?n D, Kalcsevszki R, Megyesfalvi Z, Dome B, Weiss GJ, Lohinai Z. Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status. Oncoimmunology. 2023; 12(1):2204746.

Monteiro FSM, Soares A, Rizzo A, Santoni M, Mollica V, Grande E, Massari F. The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis. Clin Genitourin Cancer. 2023 06; 21(3):324-333.

Brehm TT, Pfefferle S, von Possel R, Karolyi M, Zoufaly A, Wichmann D, Kobbe R, Emmerich P, N?rz D, Aepfelbacher M, Schulze Zur Wiesch J, Addo MM, Schmiedel S, L?tgehetmann M. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants. J Med Virol. 2022 10; 94(10):5038-5043.

Ejemel M, Smith TG, Greenberg L, Carson WC, Lowe D, Yang Y, Jackson FR, Morgan CN, Martin BE, Kling C, Hutson CL, Gallardo-Romero N, Ellison JA, Moore S, Buzby A, Sullivan-Bolyai J, Klempner M, Wang Y. A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis. Sci Rep. 2022 06 07; 12(1):9403.